

Inflammation and Cancer: The Most Recent Findings

Olumakinde Omiyale, M.Sc.¹, Rosemary Awolade, B.Sc.², Oladayo Oyetade, B.Sc.³,
Kenneth Onuh, B.Sc.⁴, Divine Chiemela, B.Sc.⁴, Goshen Odunlade, B.Sc.⁵,
Opeoluwa Shodipe, M.Sc.⁶, Muhammad Demola, M.Sc.⁷, Maro Agbanobi, B.Sc.⁸,
Adeleye Edema, B.Sc.⁹, Olanrewaju Ayeni, B.Sc.¹⁰, Happiness Samuel, B.Sc.¹¹

¹Department of Pharmacology, Toxicology and Therapeutics. College of Medicine. University of Lagos, Lagos 101014, Nigeria.

²Department of Anatomy. Faculty of Basic Medical Sciences. Ladoke Akintola University, Ogbomoso 210214, Nigeria.

³Department of Microbiology. Faculty of Science. Olabisi Onabanjo University, Ago-Iwaoye 120107, Nigeria.

⁴Department of Public Health. Faculty of Health Science. University of New Haven, West Haven 06516, United States.

⁵Department of Biotechnology. Faculty of Biological Sciences. Bells University of Technology, Ota 102213, Nigeria.

⁶Department of Microbiology. Centre of Human Virology. Nigerian Institute of Medical Research, Lagos 101014, Nigeria.

⁷Department of Biomedical Engineering, School of Engineering, University of Strathclyde, Glasgow G12 8QQ, United Kingdom.

⁸Department of Biochemistry. Faculty of Life Sciences. Delta State University, Abraka 330105, Nigeria.

⁹Department of Biochemistry. Faculty of Basic Medical Sciences. University of Ibadan, Ibadan 200005, Nigeria.

¹⁰Department of Mathematics. Faculty of Sciences. Federal University. Oye Ekiti 371104, Nigeria.

¹¹Department of Human Physiology. Faculty of Basic Medical Science. Ambrose Ali University, Ekpoma 310006, Nigeria.

Received 10 December 2023 • Revised 18 January 2024 • Accepted 25 January 2024 • Published online 3 September 2024

Abstract

An in-depth investigation into the complicated relationship between inflammation and cancer provided new findings. We explored new developments that shone a light on the involvement of inflammation in the emergence of many cancers in this study. What we know of this complex interaction has been shaped over time by historical observations that have transformed into molecular mechanistic findings. Understanding the importance of the invasion of immune cells in tumor micro-surroundings, gaining knowledge of the signaling mechanisms that control inflammation-induced carcinogenesis, and identifying inflammatory agents as possible biomarkers for diagnosis and the outlook may lead to novel therapeutic strategies and improved patient outcomes. The combination of immunotherapies and other treatment techniques offers a promising way to enhance therapeutic effects. The development of novel therapies like adoptive T-cell therapy and

Contact: Olumakinde Omiyale, M.Sc.
Department of Pharmacology, Toxicology and Therapeutics. College of Medicine.
University of Lagos, Lagos 101014, Nigeria.
E-mail: 199096019@live.unilag.edu.ng

J Health Sci Med Res 2025;43(1):e20241082
doi: 10.31584/jhsmr.20241082
www.jhsmr.org

© 2024 JHSMR. Hosted by Prince of Songkla University. All rights reserved.
This is an open access article under the CC BY-NC-ND license
(<http://www.jhsmr.org/index.php/jhsmr/about/editorialPolicies#openAccessPolicy>).

oncolytic viral therapy further emphasizes how far we have come. The need to manage immune evasion mechanisms and improve these therapeutic approaches further are still problems. We describe the intriguing possibility of using inflammation as a tool for targeted treatment for cancer in this investigation, with possibilities for better patient outcomes and alternative treatment methods.

Keywords: biomarker, cancer, immunotherapy, inflammation, tumor micro-surroundings

Introduction

The complex relationship linking between inflammation and cancer development has become a fascinating and important area of study in the large field of studies into cancer. Scientific inquiry over the past couple of decades has established a strong connection between persistent inflammation and the emergence of cancer¹. The current knowledge of the elements that contribute to cancer has been fundamentally altered by the progression from older ideas to newer-to-newer biochemical causal findings.

The earliest studies by nineteenth century scientists suggested a connection between inflammation and cancer by mentioning immune cells in tumor microenvironments in their scientific reports¹. Rudolf Virchow's groundbreaking research illuminated the recruitment of leukocytes in tumors, setting the groundwork for examining the immune system's function in the development of cancer². Using this as a base, later studies shed light on the complex interactions between immune cells, cytokines, and tumor cells, spawning the field of immunology in cancer^{2,3}.

Knowledge of these complex relationships has advanced significantly with the development of ideas and theories related to inflammation and cancer. In one important study from the 1980s, Harold Dvorak suggested the idea of "tumor angiogenesis factor," emphasizing the part that inflammation plays in encouraging angiogenesis and aiding tumor growth. This hypothesis sparked research into the role of inflammatory mediators in tumor angiogenesis, including VEGF (vascular endothelial growth factors) and interleukin-8

(IL-8)⁴. Recent discoveries have highlighted the critical function of the tumor microenvironment in directing the interaction between cancer and inflammation⁵. Immune cells, such as neutrophils, T-cells, and macrophages, have become important elements in determining the tumor microenvironment. They can affect the course of the disease and the effectiveness of treatment by either promoting immune evasion by cancer cells or anti-tumor immune responses^{6,7}.

Our knowledge has also increased as a result of comprehensive studies into the molecular mechanisms that support the development of cancer brought on by inflammation. Tumor cells surviving, dividing, and metastasizing have been linked to the nuclear factor (NF- κ B) pathway, an important controller of inflammation. The Janus kinase-signal transducer and activator of transcription (JAK-STAT) mechanism has also been linked to tumor growth induced by inflammation and resistance to treatment^{8,9}.

Inflammatory cytokines and chemokines have a role in coordinating the attraction and stimulation of immune cells inside the tumor microenvironment, according to research into their functions¹⁰. Tumor-promoting cytokines like tumor necrosis factor- α (TNF α), interleukin 6 (IL-6) and immune-suppressive myeloid cell recruitment by chemokines like chemokine (C-C motif) ligand 2 (CCL2) result in an immunosuppressive tumor microenvironment¹⁰. Inflammatory markers have been identified as potential cancer biomarkers, which has sparked curiosity about utilizing them for diagnosing cancer early and predictions.

The ability to forecast cancer risk using biomarkers like C-reactive protein (CRP) and interleukin-18 (IL-18) is already in clinical use, allowing for fast action and individualized plans for therapy^{11,12}.

The identification of the role of inflammation in the advancement of malignant tumors has prompted an investigation into novel treatment strategies, and immunotherapies, such as immune checkpoint inhibitors, which specifically target pathways of inflammation, have demonstrated remarkable effectiveness in the treatment of several forms of cancer¹³. These treatments benefit from how well the immune system is able to recognize tumors, opening up new treatment options^{13,14}. Additionally, combining immunotherapies with traditional therapy techniques has been identified as a viable approach to treatment. Immunotherapies have been used with chemotherapy, radiation therapy, and targeted medicines to strengthen immunity reactions against tumors, creating new opportunities for enhancing therapeutic results¹³.

Numerous novel medicines and active clinical trials highlight the dynamic character of this area as research advances. Adoptive T-cell treatment and oncolytic virus therapy are two cutting-edge therapeutic approaches that have the potential to use the capability of the body's immunity to identify and eradicate cancer cells^{15,16}. However, even with significant possible opportunities in this research area, some difficulties still need to be resolved. Intensive research is required to overcome the convoluted nature of the tumor microenvironment, solve immune evasion mechanisms, and mitigate probable side effects of immune therapy. Further studies must focus on the development of several indicators or biomarkers that can forecast which individuals will react most favorably to anti-inflammatory medication¹⁷.

Briefly said, scientific understanding of the biological mechanisms underpinning the link between inflammation and cancer has advanced from historical data. Recent research has revealed how inflammation has a major effect

on carcinogenesis, opening up new avenues for therapeutic approaches and better patient outcomes¹⁷. Researchers are improving our understanding of cancer by examining the complex interplay between immune cells, cytokines, and tumor cells. They are also paving the path for novel approaches that leverage the strength of inflammation for tailored cancer care.

Aims

- Investigate the intricate relationship between inflammation and cancer.
- Explore recent advancements in understanding inflammation's role in cancer development.
- Highlight new insights into the relationship that exists between tumor cells, cytokines, and immune cells.
- Examine the inflammatory agents' potential to serve as indicators regarding tumor detection and prediction.
- Evaluate the prospects of combining immunotherapies with traditional treatment techniques.
- Address knowledge gap.
- Examine the nuanced and multifaceted connection between inflammation and cancer.
- Examine the molecular mechanisms underlying inflammation-induced carcinogenesis.
- Address the therapeutic potential of targeting inflammation in cancer treatment.
- Describe the connection between historical observations and current molecular mechanistic findings in the field.
- Clarify insights into utilizing inflammation for more personalized and effective cancer treatment strategies.

Methodology

The review process's approach involved a comprehensive literature review focused on the complex relationship between inflammation and cancer. The review

covered papers from the five years prior to mid-2023, to ensure the incorporation of the most recent advancements in the field. The search for relevant publications was conducted exclusively on PubMed and Google Scholar resulting in the identification of more than 47,668 publications directly related to the specified topic. The key terms used for this search were “Cancer” and “Inflammation”.

The selection of studies was based on their exceptional contributions to understanding the interplay between inflammation and cancer, thereby establishing their significance within the field.

Inflammation and cancer: historical perspective

The quest to understand the complex relationship linking inflammation and malignant tumors began in the nineteenth century when scientists first started looking at this important relationship. As we set off on a journey through time, we learn about the amazing history of theories and hypotheses that have formed our understanding of how inflammation contributes to the development of malignancies. Early research conducted in the 1800s served as a springboard for understanding the potential linkage that exists between inflammation and cancer¹⁸. Visionary researchers noticed that the onset of some types of cancer frequently occurred concurrently with chronic inflammation, which aroused interest and motivated the pursuit of additional research. Numerous studies were conducted over the years, which helped give rise to a variety of hypotheses. According to Sir Percival Pott’s initiation–promotion principle, prolonged irritation and inflammation brought on by outside stimuli could result in the occurrence of cancer^{19,20}. The foundation for later research into the part variables in the environment play in the development of cancer was laid by this notion. The insight of “tumor–promoting” inflammation first appeared in the early years of the twentieth century²¹. The hypothesis that inflammation may affect tumor growth and progression was first raised by the discovery of inflammatory cells infiltrating tumor tissues.

This realization offered a fresh viewpoint on the connection between inflammation and cancer²².

The identification of particular inflammatory mediators and their signaling pathways in the middle of the 20th century added to our understanding. Scientists discovered how growth factors, cytokines, and chemokines coordinate the immune system’s responses and affect the behavior of cancer cells⁸. In the second part of the 20th century, the idea of the tumor microenvironment emerged, illuminating the intricate ties linking stromal, immune and tumor cells²³. More in depth analysis of the tumor ecosystem brought to light the crucial part that inflammation plays in determining the cancerous cells’ microenvironment and regulating how cancer develops.

Our capacity to look deeply into the cellular mechanisms at the nexus of inflammation and cancer increased as science and technology approaches developed. The 21st century saw the development of powerful genetic and molecular approaches, which opened up fresh perspectives on the complex interactions between inflammation and cancer²². As scientists learn new things about inflammation and cancer daily because of new methods in genomics, proteomics, and molecular biology, our knowledge of it continues to change⁷. We are getting closer to game–changing developments in cancer therapy thanks to the cooperation of cross–disciplinary experimental groups.

The historical association between inflammation and cancer have resulted in persistent interest in this complex interaction. The investigations of inflammation’s function in cancer have resulted in significant developments in cancer therapy and prevention, from its early stages in the middle of the nineteenth century to the leading–edge studies of the present day. We set out on an ever–changing path of discovery, motivated by interests and a never–ending quest to solve the secrets of cancer’s complicated nature, by advancing on the solid groundwork built by forward–thinking scholars of earlier times.

Recent advances in understanding inflammatory pathways

A. Identification of key inflammatory mediators:

Innovative findings from recent studies have increasingly linked inflammation-related disorders to crucial inflammatory mediators^{22,24}. The complicated system of cytokines, chemokines, and growth factors that controls the inflammatory response has been increasingly understood by experts, emphasizing their many roles in both healthy and pathological circumstances. The elucidation of these mediators has opened the door for specialized therapy strategies by shedding light on the molecular causes of inflammation²⁵.

1. Cytokines: Proteins called cytokines are released by immune cells and other cell types. They are essential immune-mediated signaling chemicals. The functions of certain cytokines in inflammation and disease development have been clarified by recent investigations. In particular, biologic therapies for many inflammatory illnesses target tumor necrosis factor- α (TNF α), which has been identified as a key component in chronic inflammation^{26,27}. Interleukins, a family of cytokines, play diverse roles in inflammation, immune responses, and tissue homeostasis. Advances in understanding the functions of specific interleukins have provided valuable insights into their contributions to inflammation-related diseases. For example, Interleukin-17 (IL-17), which is commonly linked to autoimmunity, has become an alternative focus for treatment²⁸.

2. Chemokines: Chemotactic proteins such as chemokines draw immune cells to areas of inflammation. The diverse functions of several chemokines in immune cell recruitment and tissue-specific inflammation have been confirmed by many studies in the literature. Also, chronic inflammation and autoimmune disorders have been tied to the deregulation of chemokine signaling²⁹.

Chemokines are peptides with a molecular mass of eight to eleven kDa that control cell-based chemotactic

movement, adhesion, localization, and interactions between cells by attaching to G-protein-coupled receptors (GPCRs). They organize immune cell recruitment into tissues, control immune cell interactions, and modulate both³⁰. Chemokines may serve as predictive indicators for a variety of blood and solid cancers since they promote tumor growth in cancer model organisms and create an immune-suppressive and secure tumor microenvironment (TME)⁶. They perform a variety of tasks, such as self-regulating chemokines that control the growth, blood vessel development, and chemotaxis of immunologic cells. Chemokines play a variety of roles in the immune response to tumors, influencing the microenvironment within the tumor that is made up of cancer cells, tissue-resident cells, and migrating immune cells. The phase of disease development, the level of immune cell stimulation, and the expression of the chemokine receptors all influence how the tumor-promoting and tumor-blocking immunological responses are balanced by the chemokine system³¹.

B. Signaling pathways involved in cancer promotion:

New discoveries from investigations into cancer have further explored the signaling pathways linking inflammation to the advancement of cancer, opening up new potential therapeutic and preventive options¹⁻³.

1. NF- κ B Signaling: Inflammation and immunological responses are mostly regulated by the NF- κ B signaling pathway. Different cancers have been linked to dysregulation of NF- κ B activation, which promotes tumor cell survival, growth, and invasion. It may be possible to stop the cancer-promoting consequences of chronic inflammation by inhibiting NF- κ B signaling¹³.

2. STAT3 Pathway: One more significant role player in inflammation-related cancer is the signal transmitter and promoter of transcription 3 (STAT3) network. Abnormal STAT3 activity has been associated with immune suppression, vascular development, and the persistence of malignancies. In some cases, inhibiting STAT3 signaling may be a viable treatment plan for therapy in cancer⁹.

3. Toll-like Receptors (TLRs): Pattern-recognizing receptors called toll-like receptors (TLRs) detect intrinsic and pathogen warning signs and trigger immune system reactions in response. Abnormal TLR activation is associated with the occurrence of malignancies and chronic inflammation. TLRs may be targeted to both reduce inflammation and slow the spread of malignancy³².

4. Inflammasomes: Pro-inflammatory cytokines like IL-1 and IL-18 are processed and secreted by multiprotein assemblies called inflammasomes. Cancer and chronic inflammatory diseases have both been linked to disrupted inflammasome activity. Pharmaceutical prospects are being explored for reducing the hazards of cancer related with inflammation by modulating inflammasome activity³³.

New options for the research and discovery of anti-inflammatory and immune-regulating cancer therapeutics are offered by recent improvements in our perceptions concerning inflammatory networks and how they function in cancer³⁴. Scientists hope to reduce the void connecting inflammation and cancer biology by focusing on the

inflammatory mediators and signaling pathways that support the growth of cancer. This will pave the way for personalized medicine strategies that focus on the inflammatory milieu in the battle aimed at cancer^{7,35}.

The possible effects of cancer preventive measures, therapy, and treatment results have become more and more clear as a scientific study of inflammation-related mechanisms progresses⁷. Researchers and practitioners are well-positioned to capitalize on the complex relationships between inflammation and cancer to put together game-changing treatment options and open up the means for the possibility in which inflammation-driven targeted therapy performs a critical role in overcoming this enormous public health problem by leveraging the capability of contemporary innovations, interdisciplinary partnerships, and cutting-edge approaches to therapy. Unquestionably, the continuous study of inflammatory pathways and their relationship to cancer will yield ground-breaking insights and raise fresh hopes for the fight against this deadly condition.




Figure 1 Inflammation causes NF-κB induction, which in turn causes the generation of pro-IL-1 and the inflammasome NLRP3's stimulation, that then causes the expression of STAT that promotes cancer cell sustenance and metastasis. (Adapted from Zhang et al. 2022¹²)

Inflammation-driven tumor microenvironment

Cancerous tumor cells engage a variety of cells from the stromal area, antibody-producing cells, and matrix material elements in the complex and changing tumor surroundings. New studies on the inflammatory tumor milieu have highlighted its critical function in the onset, advancement and response to treatment of cancer³⁶.

A. Immune cells and their impact on tumor progression

Recently published work has emphasized the numerous functions of immune system cells, including dendritic cells, macrophages, T-lymphocytes, and B-cell lymphocytes, inside the tumor surroundings^{1-3,37}. In accordance with their physical characteristics and roles, cells of the immune system can either stimulate or inhibit the formation of tumors. The delicate equilibrium involving inflammation-related immune system reactions that are pro- and anti-inflammatory has major effects on the course of cancer and the health of sufferers³⁸.

B. Tumor-associated macrophages (TAMs)

TAMs exert a considerable influence on the tumor's microenvironment, have considerable flexibility and serve a variety of purposes. TAMs can take on many phenotypes, such as inflammation-promoting M1-type or anti-inflammation M2-type morphologies, depending on the inflammatory environment. Their presence in the tumor microenvironment is linked to immune system avoidance, vasculature enhancement, and pro-malignancy activities³⁸.

C. T-cells and cancer immunotherapy

In monitoring immune function and the production of cytotoxic agents against tumors, T-lymphocytes are essential players. Through the use of T-lymphocytes (as in Adoptive T-cell therapy) in attacking tumor-specific antigenic substances, recent developments in immune therapy for cancer have produced remarkable therapeutic outcomes in several cancer types. For immunotherapeutic techniques to be optimized and resistance to be overcome,

further studies are required on the interactions between T-cell interaction involving T-lymphocytes and the tumor surroundings³⁷.

D. Cytokines and chemokines' function in modulating the microenvironment

Cytokines and chemokines are important inflammation-related substances that control interactions between cells and the immune system. Their secretion and signaling have an impact on the growth, spread, metastasis, and influx of immune cells, as well as other aspects of oncology. The tumor milieu can be modified, and healthcare results can be improved by focusing on particular cytokines and chemokines³⁹.

E. Extracellular matrix remodeling and cancer progression

The region that surrounds the cells may undergo significant remodeling as a result of inflammation, changing the structural makeup of the tissue and contributing to tumor infiltration and spread. Recent studies have shed light on the function of inflammatory elements in the breakdown of extracellular matrices and the spread of cancer cells, including matrix metalloproteinases (MMPs). Inhibiting the activity of MMPs and other matrix-modifying enzymes may reduce the spread of cancer and increase patient survival⁴⁰.

F. Therapeutic implications of the tumor microenvironment

Understanding the complexity of the inflammation-driven tumor microenvironment has significant implications for cancer therapy. By triggering anti-tumor immune responses, inhibiting immunological checkpoints like cytotoxic T-lymphocyte-associated antigen 4 (PD-1)/programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) has transformed the way that cancer is treated^{37,41,42}. Additionally, combined approaches involving immunotherapies, chemotherapy, and targeted therapies are being explored to eliminate resistance to medications and improve a patient's

chances of survival⁴³. The inflammation-driven tumor microenvironment represents a critical nexus where cancer cells, immune cells, and stromal components interact in a complex interplay that influences cancer development and treatment responses²⁹. Recent advances in this field have offered useful perspectives into the multifaceted functions of immune cells, the effects of cytokines and chemokines, and the transformation of the extracellular matrix in tumor growth²⁹. Armed with this knowledge, researchers and clinicians are poised to change the landscape of malignant tumor care, create novel approaches to immune-mediated therapy for cancer and targeted therapy, and improve patient outcomes. As we continue to decipher the intricacies of the inflammation-driven tumor microenvironment, we step closer to a future where personalized and targeted therapies provide improved care and bring hope to conquering cancer and bringing hope to patients worldwide.

Inflammatory markers as potential cancer biomarkers

In the field of oncology, the quest for good and easily quantified cancer biomarkers remains active. Inflammatory indicators have received a lot of attention as prospective cancer biomarkers recently, giving promising opportunities for early detection, prognostication, and therapy response prediction in a variety of cancer types⁴⁴.

A. Inflammatory signaling and cancer pathogenesis

Inflammation has an impact on the growth of blood vessels, the development of tumors, and the spread of cancer. Although blood-based diagnostics only work on advanced cancer, the identification of inflammatory markers can result in the development of novel cancer preventive and therapy strategies⁴⁴.

Patients with metastatic uterine cancer have been reported to benefit from the therapeutic effects of phosphoglycerate kinase 1 (PGK1)⁴⁵. Various studies

have reported that patients with raised PGK1 levels had higher rates of failing to respond to first-line treatment^{46,47}. African American men with prostate cancer are frequently highlighted for tumor resistance to treatments^{41,48}.

The nuclear mammalian target of rapamycin (mTOR) has been shown to be elevated among people with prostate cancer and other metastatic malignancies such as lung, breast, and colon cancer. Prostate cancers and microRNA disruption are linked to microRNA-99b-5p suppression^{41,42,49}. Changes in DNA damage response genes (DDRGs) can foretell how a patient will respond to cisplatin therapy. The increased inflammatory response caused by COVID-19 has been associated with a number of age-related diseases, including cancer, and may hasten the aging process⁵⁰⁻⁵⁵. Neopterin (NPT) is a shared feature of different cancer subtypes as well as Duchenne muscular dystrophy (DMD). Impaired respiratory function has been examined in studies with DMD and genetically modified humanized mice given the spike protein (SP) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)^{54,55}.

B. Cytokines and chemokines as biomarkers

Central mediators of the inflammatory response, cytokines and chemokines have shown promise as potential cancer biomarkers. In order to determine a possible correlation with the existence, phase, and severity of malignancy, many current studies are concentrating on determining the concentrations of particular cytokines and chemokines in blood or tissue samples⁵⁶. Different cytokine and chemokine profiles may reveal crucial data for the detection and outlook of cancers⁵⁶.

1. C-reactive protein (CRP) and interleukin-18 (IL-18)

According to US FDA guidelines, CRP is one protein which may be accurately quantified from blood using a variety of techniques. Standard CRP levels (10 g/ml) as well as elevated sensitivity CRP levels (10 g/ml) are two quantitative limits. CRP assessments are helpful for

assessing the degree of progression of the disease since elevated levels of CRP are closely related to late-stage illness in a variety of malignancy phases⁵⁷.

2. IL-18

The significance of IL-18 in tumor advancement with its relationship to patient prognosis and immune cell recruitment were examined in a research investigation by Gil M and Kim KE⁵⁸. Although IL-18 mRNA levels have been found to be significantly lower in melanoma cells, patient prognosis is favorably connected with them⁵⁸. Perforin and granzyme B activity indicate a positive correlation with IL-18 levels, which enhances an invasion of cluster of differentiation 8 (CD8+) T and Natural Killer cells. This suggests that IL-18 could serve as a prognostic marker for the long-term prognosis of melanoma⁵⁸.

C. Immunological biomarkers and cancer immunotherapy

By leveraging the body's own immune system, this innovative therapeutic strategy has shown remarkable potential in the fight against cancer^{11,12}. Immune cell subgroups and cytokine counts are examples of inflammatory markers that have been investigated as potential biochemical indicators for immunotherapy effectiveness. Making the most effective care options and enhancing clinical results may be possible if it is possible to determine individuals whose immune systems are at greater risk of negatively reacting to immune-mediated therapy⁶.

D. Inflammatory markers in liquid biopsies

Liquid biopsies have created novel possibilities for non-intrusive tumor surveillance and diagnosis. Inflammatory indicators can be seen in blood, urine, or other types of body fluids, including systemic inflammatory chemicals and cell-free DNA such as CD44-related markers associated with T-cell activation capable of being used to predict malignancy, CRP, neutrophil-to-lymphocyte ratio (NLR), lactate dehydrogenase (LDH) and tumor-derived exosomes (TDEs), vesicles released by tumor cells that can contain

various inflammatory markers, etc^{44,57}. Liquid biopsies could possibly identify cancer very early and provide actual time reaction to therapy tracking while relieving patients from invasive practices and revealing important medical data⁵⁹.

Challenges and future Perspectives

Inflammatory indicators as cancer biomarkers have strong potentials, but there are still challenges in their use due to limitations in sensitivity and specificity⁴⁴ which limit their widespread clinical usage. Future research aims to develop more sensitive marker panels as inflammatory markers such as C-reactive protein and erythrocyte sedimentation rate (ESR) show low sensitivity in detecting cancer, rendering them inappropriate as independent tests^{55,57}. Chronic inflammation is also linked to immune escape, promoting tumor development. An interdisciplinary approach and long-term research are needed to develop reliable indicators and confirm their clinical usefulness⁴⁴.

Inflammation and cancer treatment strategies

A positive new frontline in the fight against cancer is the incorporation of inflammation-driven cancer treatment approaches into the oncological arsenal.

A. Targeting inflammatory pathways for cancer therapy

The focus of many cancer therapeutic research has shifted to the targeting of particular inflammatory pathways. In order to disrupt pathways that promote cancer, small molecule inhibitors, monoclonal antibodies, and other targeted treatments have been developed to interfere with crucial elements of inflammatory signaling, such as NF- κ B, STAT3, and cyclooxygenase-2 (COX-2)^{8,9}.

B. Immunotherapies harnessing the inflammatory response

By equipping the body's natural defenses to identify and eliminate cells that are cancerous, immunotherapies targeting cancer have significantly changed the direction

of cancer care. Anti-PD-1/PD-L1 and anti-CTLA-4 antibodies, among other immune checkpoint blockers, exhibit beneficial progress in a range of cancer types⁴². These immunotherapies use inflammation to counteract resistance and support long-lasting tumor fighting immunity^{6,42,37}.

C. Combinational approaches for enhanced efficacy

The tumor surroundings are a complicated biosphere wherein there is interplay between a number of variables which influences the development of cancer²⁴. To improve treatment effectiveness, new strategies may combine conventional medicines with immunotherapies or specific medications. These integrated approaches show possibilities in eliminating resistance to therapies and providing better results for patients by utilizing the efficacy of the inflammation response to boost immune identification of malignant cells^{23,43}.

D. Inflammation-targeted radio-sensitization

The mainstay of medical care for cancer, gamma ray therapy, causes harm to genetic material and leads to cell suicide. Recent studies have looked into how inflammation-targeted radio-sensitization might improve the effectiveness of radiation therapy³⁵. A fresh opportunity to improve radiation therapy and reduce side effects is provided by the ability of inflammatory mediators to modify the irradiation reaction in tumor cells and nearby cells and tissues⁶⁰.

New technologies have increased the accuracy of radiation in treating cancerous growths and minimizing damage to healthy tissues. Treatment effectiveness has increased with greater knowledge of radiobiology, notably radiation sensitivity and tolerance^{13,61}. Several radiation sensitizers and protectors have been created, but with mixed results indicating that more work needs to be done. Additional hope is provided by personalized medicine, which considers genetic differences, transcriptomes, proteomes, and immunity to cancer⁶².

1. Targeting tumor hypoxia

Solid malignancies frequently exhibit hypoxia, which has an impact on the outcome of numerous cancers. Hyperbaric oxygen and other hypoxic radiosensitizers increase locoregional regulation and freedom from disease. Aiming at hypoxia, though, has not had a clinically significant effect on radiation sensitization⁶³.

2. Targeting radiation-induced DNA damage response signaling

Apoptosis is brought on by radiation-triggered DNA injury, notably double stranded breaks (DSB). Radiation resistance in breast tumors is caused by the poor-functioning breast cancer gene 1 (BRCA1,2), which encodes a DNA DSB repair mechanism⁶⁴.

3. Identifying a gene signature for radio-response prediction

Personalized treatment is made possible by advances in genomic analysis, which help uncover breast cancer propensity regions, radiation-resistance genes, and recuperating radiotherapy results ratings. These developments have also improved patient outcomes for head and neck squamous cell carcinoma (HNSCC) and prostate cancer⁶⁵.

4. Identifying radiation toxicity genes in normal tissues

The poor quality of life endured by cancer sufferers is impacted by irradiation damages in healthy tissues such as immediate radiotoxicity and chronic sequelae such as telangiectasia, fluid retention, and scarring through intricate molecular pathways¹³.

E. The role of inflammatory markers in treatment response prediction

Inflammatory markers have come into focus as potential predictors of cancer patients' treatment outcomes. A shift in the concentrations of particular cytokines, chemokines, or immune cell subsets may offer important clues about how well a treatment works. Clinicians can

evaluate treatment response and change treatment regimens as necessary by monitoring inflammatory indicators (CD44-related markers such as CD44v35; is a criterion for rare cell abnormality and early-stage cancer. CD80; is a ligand for CTLA-4, inhibiting T-cell function. Tumors can subvert these interactions for immune escape and also CD86; is associated with poor treatment outcomes in some cancer types. Then Neutrophil-to-lymphocyte ratio (NLR), Lactate dehydrogenase (LDH) and Tumor-derived exosomes (TDEs) while patients are receiving medication)^{10,26,66–68}.

F. Precision Medicine and Inflammation-driven cancer therapy

Personalized medicine seeks to tailor therapeutic regimens in accordance with unique patient traits, such as tumor genetic profiles and immunological condition⁶⁴. By selecting medicines that specifically target particular inflammatory pathways or immunological checkpoints, allowing healthcare providers to maximize therapeutic efficacy while minimizing side effects by being aware of the inflammatory surroundings of each patient's malignancy⁶⁷.

1. Personalized radiation-immunotherapy

Genomic unpredictability, which results in the production of neoantigens, is an important characteristic of many cancers characteristic of cancer. Major histocompatibility complex (MHC) frameworks manage the presentation of these neoantigens and recognition of CD8+ T-cell receptors (TCR)⁴³. Computational prediction of neoantigen peptide binding to MHC is a key step in current clinical trials using TCR-T cell therapies. Immunotherapy, for instance PD-1 and CTLA-4 inhibition, tends to be more effective in treating patients with genetic instability. Radiotherapy impairment, signals from inflammatory processes, and neoantigens can all have an impact on the biomarker neoantigen load, which is used in the treatment of cancer. In progressed urothelial cancer, one study reported a greater correlation between

immunotherapy reaction and mismatch repair deficiency (MMR), that is the presence of MMR deficiency has been shown to have implications for immunotherapy efficacy, with MMR-deficient tumors exhibiting a higher mutational burden and increased response to PD-1 blockade⁶⁸.

2. Precision medicine and inflammation-driven cancer therapy

The outcome for proinflammatory breast cancer is mostly very poor, even with advancements in management. Pharmaceutical research utilizing conventional chemotherapeutics, targeted medicines, and immunotherapy requires a thorough understanding of inflammatory breast cancer biochemistry. The development of blood vessels estimated glomerular filtration rate (eGFR), JAK/STAT, and the phosphatidylinositol-3-kinase (PI3K)/AKT, and the mammalian target of rapamycin (PI3K/AKT/mTOR) are examples of stimulated processes, however, their human studies efficacy is constrained. For example, biomechanical stimulation promotes blood vessel growth despite VEGFR-2 inhibition, indicating that both mechanical and biochemical stimuli can lead to increased VEGFR-2 activation posing challenges in inhibiting blood vessel growth⁶⁷.

3. Precision medicine-identifying the right drug

In contrast to the limits of single gene mutational analysis, genetically complex tumors need extensive characterization utilizing DNA next-generation sequencing (NGS) for personalized treatment. Companion diagnostics are required to connect specific medications with unique genes⁶⁹.

4. Correct dosage and timing for targeted therapy

Highly efficient cancer care depends on tracking therapy reaction, though it may prove difficult to anticipate resistance and relapse and to identify biologic indicators, particularly in people who have solid tumors⁷⁰.

5. Current progress in clinical trials for pediatric precision oncology

Children's tumor genomics studies are limited, despite the positive outcomes of genomic tailored therapy for mature individual tumors. Repotrectinib, Ras-Raf-MEK-ERK (mitogen-activated protein kinase/ERK kinase)/ERK (extracellular-signal-regulated kinase) pathway targets, and anaplastic lymphoma kinase (ALK) blockers are likewise being researched^{63,71}.

By using the immunity system's ability to recognize and destroy cancer cells, immunotherapies, aiming to provide customized treatments to suit the patient's level of immune function and tumor features, personalized medicine techniques choose the best immunotherapy process for the best possible treatment outcomes^{66,67}. We foresee even more finely honed and individualized immunotherapeutic approaches in the future as research works to analyze the interaction between the immune system and the tumor.

Challenges and future directions

Notwithstanding the potential of inflammation-driven therapy for cancer approaches, difficulties still exist in implementing these findings in clinical settings. The areas which require further studies and development of novel approaches include controlling therapy-related toxicities, resolving therapy resistance, and selecting appropriate individuals who will respond best to particular medicines⁶⁸.

Emerging therapies and clinical trials

The emerging medicines and clinical investigations stand out as a ray of hope in the complex world of cancer research and care, presenting great chances to transform cancer treatment⁴¹. A rise in interest in cutting-edge therapy techniques that target inflammatory pathways, and the tumor microenvironment has been brought on by recent advances^{42,44}.

A. Therapeutic approaches targeting inflammatory pathways

A wide range of prospective therapy options are provided by the central function inflammation plays in the initiation and spread of malignancy. In order to stop cancer development and spread, emerging medicines are being tested that target important inflammatory signaling pathways such JAK-STAT, NF- κ B, and PI3K/AKT. By specifically deploying autologous tumor-invading lymphocytes and tumor-associated antigenic compounds (TAA), oncolytic viruses and adoptive T-cell therapy have the potential to revolutionize the way cancer is treated^{60,72-74}.

1. Oncolytic viruses

In light of recent improvements in viral administration and anticancer effectiveness, oncolytic viruses, which are reproducible by themselves and selectively lyse malignancies, provide single-agent therapeutic results. In the past 15 years there have been many studies on virus strains possessing anticancer capabilities, and several are now going through phase I-III clinical trials^{71,73,74}.

Clinical trials

Intratumoral injections have been mostly utilized in human studies for oncolytic viruses, while some research has also looked at infusion administration. The overall anticancer effectiveness is low, despite impressive biocompatibility and safety profiles. Oncolytic virotherapy may have prospects due to the success of low single-agents like ONYX-015^{61,62,75-77}.

More information

Tumor-associated antigenic compounds (TAA) were found to have a significant role in the immune system's ability to alter the immune response and actions of malignancies. Potent immunity against cancer cannot be produced without consideration of tumor-associated distress signs. An effective method of immune-mediated treatment is oncolytic virotherapy, which combines the accelerated release of TAA caused by carcinoma apoptosis and

distress signs. Oncolytic viruses may increase the tumor microenvironment's immune response, which may have an impact on the emergence of beneficial immune responses. It is anticipated that tumor cell death will increase the amount of tumor antigens (TAA) that dendritic cells (DC) can absorb¹⁶.

Future directions: synergistic treatment

Exploiting the immunotherapeutic abilities of oncolytic viruses through combination treatments treatment is a viable strategy. Virus administration and adoptive cellular treatment are innovative ideas with great potential, but they are constrained by T-cell trafficking⁷⁵.

Antigen-specific adoptive T-cell therapy plus oncolytic virus administration has demonstrated improvement over other treatment methods alone. Human studies are now underway on monoclonal antibodies having immune system modulatory capabilities, such as anti-cytotoxic T-lymphocyte antigen (CTLA4) and anti-Vascular Endothelial Growth Factor antibodies. Oncolytic reovirus and radiotherapy can work together cooperatively to improve T-cell trafficking and the presentation of antigenic molecules^{75,76}.

2. Adoptive T-cell therapy

Adoptive cell transfer (ACT) involves the administration of a population of cells, usually originating from the patient's immune system or another person, in order to improve immune function. Allogeneic treatments involve the extraction and cultivation of cells from a donor who is genetically distinct from the recipient, while autologous cancer immunotherapy involves the collection of T-cells from the patient's own body⁷⁷.

ACT, tumor vaccines, and immunotherapy, such as immune checkpoint inhibitors, have influenced the way that cancer is treated by inducing the immune system's ability to eliminate cancerous cells and reestablish immunological function. ACT, a biological approach that employs living cells, has produced encouraging outcomes in the treatment

of blood cancers. Tumor-invading lymphocytes (TIL) therapy enhances antitumor effects by enriching CD8+ T cells and depleting regulatory T cells (Tregs), promising melanoma treatment and exploring for other solid tumors⁷⁸. Despite being experimental, it's a promising immunotherapy research area., researchers are creating novel ACTs built around Chimeric Antigen Receptors technology, and clinical investigations are increasing^{78,79}.

Process

In order to generate lymphocytes, melanoma tumors are broken down into one-cell cultures. Within two to three weeks, these cells eliminate malignancies. They create clean cultures and enable reactivity testing⁷⁹. It costs \$75,000 to create modified T-cells, and interleukin-21 could improve their performance⁶³. Strep-tag II genetic sequences became initially available in 2016 to help with the cyclic guanosine monophosphate (cGMP) manufacture of modified T-cells. The results of therapy are correlated with development state, growth, and longevity⁶⁴.

Research progress

Rosenberg found that individuals with tumors that had spread might use autologous tumor-invading lymphocytes in adoptive cell therapy to cause shrinkage of the tumor^{65,72}. Having an Objective Response Rate (ORR) of 50.0–71.0% and a full response rate of 27.0%, another investigation by Rosenberg in 2014 produced encouraging findings^{68,73}. Tumor-invading lymphocytes therapy has been reported in one study to promote the remission of advanced cervical carcinoma^{69,73}.

B. Cytokine-based therapies

Considering their numerous roles in immunological control and inflammation, cytokines have attracted attention as possible therapeutic agents in the fight against cancer. In preclinical and clinical investigations, cytokine-based treatments, such as IL-2 and IL-12, have demonstrated positive outcomes by either increasing anti-tumor immune responses or by directly triggering cancer apoptosis. The

development of cytokine-based therapeutics offers the potential to increase the range of available cancer therapy choices⁷⁰.

1. Human drug studies for the CCL2/C–C motif chemokine receptor 2 (CCR2) axis

Carlumab and MLN1202 are two medications that have been studied in human trials that modulate the CCL2/CCR2 transduction axis, although 12.1% of patients did not show significant improvement in their health status despite the treatment being administered^{70–71}.

2. The function of the CCL5/CCR5 axis in the development of cancer and human studies of medications that target the axis

Breast tumors, leukemia that is acutely lymphocytic, myeloma multiplex, lymphoma of the Hodgkin variety, and colorectal tumors all have tumor cells that overproduce CCL5 and its receptor, CCR5⁷². Healthy duct epithelial cells or harmless breast growth rarely contain CCL5, but malignancies can produce it. Breast malignancies induce mesenchymal stem cells (MSCs) to re-produce CCL5, that

has a paracrine effect on tumor cells, according to *in vivo* studies⁷³. The CCL5/CCR5 axis affects the development of blood-related cancers as well; greater levels have been found in acute myeloid leukemia patients, and tissue from Hodgkin lymphomas secretes more CCL5 than normal. The CCR5/CCL5 axis promotes growth of cancer cells, spread, and immune-modulating TME, and is essential for the development of a variety of solid malignancies⁷⁴.

The aforementioned findings imply, in brief, that CCL5 and CCR5 are abundantly produced in a variety of cancers and encourage tumor growth and spread by enlisting immune cells. We hypothesize that CCL5/CCR5 may be an avenue for intervention in cancer care due to the observation that CCR5 antibodies slow tumor development and decrease blood vessels development⁷⁵.

The growth of malignancies depends on the CCL5/CCR5 pathway and can be inhibited by employing CCR5 blockers and antibody destruction to block CCL5. Studies in humans for medications that target this axis, such as maraviroc, vicriviroc, AZD5672, and leronlimab, that are




Figure 2 The CCL2/CCR2 signaling axis regulates CCL2 and CCR2 expression, which is involved with tumor cell behaviors and aids in the study and therapeutic management of cancer. (Adapted from Aldinucci et al., 2020⁷⁶)

being administered for the treatment of Kaposi's sarcoma, late breast, and pancreatic ductal malign and terminal CRC, are now underway. The safety and effectiveness of cenicriviroc, a double chemokine receptor inhibitor, are currently being examined^{77,78}.

3. The CCL19/CCL21/CCR7 pathway's functions in the development of cancer

Antigen exposure for immune response and T-cell-driven reactions are greatly influenced by the CCL19/CCL21/CCR7 transduction axis⁷⁹. By boosting the immune system's reaction, boosting CCL19 and CCL21 levels in tumors may help immune-oncology treatment. Direct administration of the CCL19 protein enhanced DCs, CD4+ and CD8+ T-cells and decreased immunosuppressive markers in mice lung and colorectal carcinoma models, thereby slowing cancer development⁷⁹.

4. The CCL20/CCR6 axis in cancer progression

High CCL20 production has been linked to poor prognosis in patients suffering from cancers of the liver, and the CCL20/CCR6 axis has been associated with tumor growth and migration in the tumor micro-environment^{80,81}.

C. Modulating the tumor microenvironment

A tumor's growth and spread depend on the intricate interactions of cells of the immune system and surrounding (stromal) cells that creates the tumor microenvironment. The goal of emerging therapies is to alter the tumor microenvironment to improve medication delivery, decrease angiogenesis, and stimulate anti-tumor immune responses. These novel methods offer a chance for combating resistance to therapy and improving the efficacy of already-available medicines^{6,7}.

D. Clinical trials: advancing therapeutic frontiers

Clinical trials act as a springboard for turning potential breakthroughs in science into real advantages for patients. Trials in humans are actively evaluating novel medicines that target pathways mediated by inflammation to determine their safety, effectiveness, and best course

of action⁸². Participating in clinical trials gives patients access to innovative medicines while also advancing our understanding of novel therapies and enhancing methods of therapy.

Challenges and future directions

The search for advanced cancer medicines will not be without difficulties. Among the major challenges that doctors and scientists work to resolve include ensuring patient safety, optimizing medication combos, limiting potential unwanted effects, and drug resistance⁸³. In order to advance and address these issues, collaboration between educational organizations and advocacy groups for patients will be of great help.

Conclusion

The coming years of cancer therapy are being shaped by new treatments and research trials. The investigation of novel therapeutic methods has the prospect of revolutionizing cancer care and improving patient outcomes as our knowledge of inflammation's function in cancer continues to grow. We are on the verge of a new age in cancer treatment, one characterized by individualized, efficient, and less harmful medicines, thanks to the adoption of precision healthcare, immunotherapies, and targeted treatments that focus on inflammatory pathways and the tumor milieu. Clinical trials are the first step in transforming novel findings from the forefront of research into revolutionary methods that have the capacity to change the face of cancer treatment and enhance the lives of millions of patients worldwide.

References

1. Soto-Hereder G, Gómez de Las Heras MM, Gabandé-Rodríguez E, Oller J, Mittelbrunn M. Glycolysis – a key player in the inflammatory response. *FEBS J* 2020;287:3350–69. doi: 10.1111/febs.15327.

2. Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. *Front Immunol* 2018;13:9:754. doi: 10.3389/fimmu.2018.00754
3. Ferrara N. VEGF and the quest for tumour angiogenesis factors. *Nat Rev Cancer* 2002;2:795–803.
4. Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. *Pharmacol Ther* 2021;221.
5. Gun SY, Lee SWL, Sieow JL, Wong SC. Targeting immune cells for cancer therapy. *Redox Biol* 2019;25:101174.
6. Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. *Immunity* 2019;51:27–41. doi: 10.1016/j.immuni.2019.06.025.
7. Rah B, Rather RA, Bhat GR, Baba AB, Mushtaq I, Farooq M, et al. JAK/STAT Signaling: molecular targets, therapeutic opportunities, and limitations of targeted inhibitions in solid malignancies. *Front Pharmacol* 2022;13:821344.
8. Ni Y, Low JT, Silke J, O'Reilly LA. Digesting the role of jak-stat and cytokine signaling in oral and gastric cancers. *Front Immunol* 2022;13:835997. doi: 10.3389/fimmu.2022.835997
9. Lan T, Chen L, Wei X. Inflammatory Cytokines in Cancer: Comprehensive Understanding and Clinical Progress in Gene Therapy. *Cells* 2021;10:100. doi: 10.3390/cells10010100.
10. Watson J, Salisbury C, Banks J, Whiting P, Hamilton W. Predictive value of inflammatory markers for cancer diagnosis in primary care: a prospective cohort study using electronic health records. *Br J Cancer* 2019;120:1045–51. doi: 10.1038/s41416-019-0458-x.
11. Ravindranathan D, Master VA, Bilén MA. Inflammatory markers in cancer immunotherapy. *Biology (Basel)* 2021;10:325. doi: 10.3390/biology10040325.
12. Zhang Z, Liu X, Chen D, Yu J. Radiotherapy combined with immunotherapy: the dawn of cancer treatment. *Signal Transduct Target Ther* 2022;7:258. doi: 10.1038/s41392-022-01102-y.
13. Dougan M, Luoma AM, Dougan SK, Wucherpfennig KW. Understanding and treating the inflammatory adverse events of cancer immunotherapy. *Cell* 2021;184:1575–88. doi: 10.1016/j.cell.2021.02.011.
14. Evgin L, Vile RG. Parking CAR T Cells in Tumours: Oncolytic Viruses as Valets or Vandals? *Cancers (Basel)* 2021;13:1–14.
15. Marchini A, Daeflér L, Pozdeev VI, Angelova A, Rommelaere J. Immune conversion of tumor microenvironment by oncolytic viruses: the protoparvovirus H-1PV case study. *Front Immunol* 2019;10:1848. doi: 10.3389/fimmu.2019.01848.
16. Liu C, Yang M, Zhang D, Chen M, Zhu D. Clinical cancer immunotherapy: Current progress and prospects. *Front Immunol* 2022;13. doi: 10.3389/fimmu.2022.961805.
17. Korniluk A, Koper O, Kemona H, Dymicka-Piekarska V. From inflammation to cancer. *Ir J Med Sci* 2017;186:57–62.
18. Nunney L, Maley CC, Breen M, Hochberg ME, Schiffman JD. Peto's paradox and the promise of comparative oncology. *Philos Trans R Soc Lond B Biol Sci* 2015;370:20140177. doi: 10.1098/rstb.2014.0177.
19. Pukkala E, Martinsen JI, Lynge E, Gunnarsdóttir HK, Sparén P, et al. Occupation and cancer-follow-up of 15 million people in five Nordic countries. *Acta Oncol* 2009;48:646–790. doi: 10.1080/02841860902913546.
20. Maman S, Witz IP. A history of exploring cancer in context. *Nat Rev Cancer* 2018;18:359–76.
21. Singh S, Anshita D, Ravichandiran V. MCP-1: Function, regulation, and involvement in disease. *Int Immunopharmacol* 2021;101.
22. Chen Y, Zeng Y, Zhu X, Miao L, Liang X, Duan J, et al. Significant difference between sirolimus and paclitaxel nanoparticles in anti-proliferation effect in normoxia and hypoxia: The basis of better selection of atherosclerosis treatment. *Bioact Mater* 2020;6:880–9.
23. Mehu M, Narasimhulu CA, Singla DK. Inflammatory cells in atherosclerosis. *Antioxidants (Basel)* 2022;11:233. doi:10.3390/antiox11020233.
24. Kany S, Vollrath JT, Relja B. Cytokines in Inflammatory Disease. *Int J Mol Sci* 2019;20:6008. doi:10.3390/ijms20236008.
25. Agbaje EO, Charles OO. Anti-inflammatory and cytokines modulatory activities of spondias mombin linn.(Anacardiaceae) in wound healing: roles of IL6. *J Phytopharmacol* 2022;23:24. doi: 10.31254/phyto.2022.11406.
26. Morita TCAB, Criado PR, Criado RFJ, Trés GFS, Sotto MN. Update on vasculitis: overview and relevant dermatological aspects for the clinical and histopathological diagnosis – Part II. *An Bras Dermatol* 2020;95:493–507. doi: 10.1016/j.abd.2020.04.004.
27. Li H, Wu M, Zhao X. Role of chemokine systems in cancer and inflammatory diseases. *MedCom* 2022;3:e147. doi: 10.1002/mco2.147.

28. Crijns H, Vanheule V, Proost P. Targeting chemokine-glycosaminoglycan interactions to inhibit inflammation. *Front Immunol* 2020;11:483. doi:10.3389/fimmu.2020.00483.
29. Do HTT, Lee CH, Cho J. Chemokines and their receptors: multifaceted roles in cancer progression and potential value as cancer prognostic markers. *Cancers (Basel)* 2020;12:287. doi: 10.3390/cancers12020287.
30. Duan T, Du Y, Xing C, Wang HY, Wang RF. Toll-like receptor signaling and its role in cell-mediated immunity. *Front Immunol* 2022;13:812774. doi: 10.3389/fimmu.2022.812774.
31. Briukhovetska D, Dörr J, Endres S. Interleukins in cancer: from biology to therapy. *Nat Rev Cancer* 2021;21:481–99. doi: 10.1038/s41568-021-00363-z
32. Xu M, Zhang T, Xia R, Wei Y, Wei X. Targeting the tumor stroma for cancer therapy. *Mol Cancer* 2022;21:208. doi: 10.1186/s12943-022-01670-1.
33. Marshall JS, Warrington R, Watson W, Kim HL. An introduction to immunology and immunopathology. *Allergy Asthma Clin Immunol* 2018;14(Suppl 2):49. doi:10.1186/s13223-018-0278-1.
34. Feng Y, Ye D, Wang Z, Pan H, Lu X, Wang M, et al. The Role of Interleukin-6 Family Members in Cardiovascular Diseases. *Front Cardiovasc Med* 2022;9:818890.
35. Winkler J, Abisoye-Ogunniyan A, Metcalf KJ, Werb Z. Concepts of extracellular matrix remodelling in tumour progression and metastasis. *Nat Commun* 2020;11:5120. doi: 10.1038/s41467-020-18794-x.
36. Zeng L, Ma G, Chen K, Zhou Q. Bibliometric analysis of rheumatic immune related adverse events associated with immune checkpoint inhibitors. *Front Immunol* 2023;14:1242336. doi: 10.3389/fimmu.2023.1242336.
37. Wojtukiewicz MZ, Rek MM, Karpowicz K, Górska M, Polityńska B, Wojtukiewicz AM, et al. Inhibitors of immune checkpoints–PD-1, PD-L1, CTLA-4–new opportunities for cancer patients and a new challenge for internists and general practitioners. *Cancer Metastasis Rev* 2021;40:949–82.
38. Zhu Y, Liu J. The role of neoantigens in cancer immunotherapy. *Front Oncol* 2021;11:682325. doi: 10.3389/fonc.2021.682325.
39. Tappia PS, Ramjiawan B. Biomarkers for Early Detection of Cancer: Molecular Aspects.– *Int J Mol Sci* 2023;24:5272. doi: 10.3390/ijms24065272.
40. Koguchi D, Matsumoto K, Ikeda M, Shimizu Y, Nakamura M, Shiono Y, et al. Gemcitabine–Paclitaxel chemotherapy for patients with advanced urothelial cancer refractory to cisplatin-based chemotherapy: predictive role of pgk1 for treatment response to cytotoxic chemotherapy. *Int J Mol Sci* 2022;23:12119. doi: 10.3390/ijms232012119.
41. Gujrati H, Ha S, Waseem M, Wang BD. Downregulation of miR-99b-5p and upregulation of nuclear mTOR cooperatively promotes the tumor aggressiveness and drug resistance in African American prostate Cancer. *Int J Mol Sci* 2022;23:9643. doi: 10.3390/ijms23179643.
42. Niture S, Tricoli L, Qi Q, Gadi S, Hayes K, Kumar D. MicroRNA-99b-5p targets mTOR/AR axis, induces autophagy and inhibits prostate cancer cell proliferation. *Tumour Biol* 2022;44:107–27. doi: 10.3233/TUB-211568.
43. Yoshida T, Kates M, Fujita K, Bivalacqua TJ, McConkey DJ. Predictive biomarkers for drug response in bladder cancer. *Int J Urol* 2019;26:1044–53.
44. Sucher R, Schroecksnadel K, Weiss G, Margreiter R, Fuchs D, Brandacher G. Neopterin, a prognostic marker in human malignancies. *Cancer Lett* 2010;287:13–22.
45. Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. *Nat Rev Endocrinol* 2018;14:576–90.
46. Tayeri K, Asadollahi K, Madani N, Haghooy Javanmard S. Does COVID-19 escalate aging process? a possible concern. *Adv Biomed Res* 2022;11:106. doi:10.4103/abr.abr_350_21.
47. Vita GL, Politano L, Berardinelli A, Vita G. Have duchenne muscular dystrophy patients an increased cancer risk? *J Neuromuscul Dis* 2021;8:1063–7.
48. Jones L, Naidoo M, Machado LR, Anthony K. The Duchenne muscular dystrophy gene and cancer. *Cell Oncol (Dordr)* 2021;44:19–32.
49. Roi A, Roi CI, Negrutiu ML, Riviş M, Sinescu C, Rusu LC. The Challenges of OSCC Diagnosis: Salivary Cytokines as Potential Biomarkers. *J Clin Med* 2020;9:1–16.
50. Ma L, Jiang F, Fan X, Wang L, He C, Zhou M, et al. Metal-organic-framework-engineered enzyme-mimetic catalysts. *Advanced Materials* 2020;32:2003065.
51. Gil M, Kim KE. Interleukin-18 is a prognostic biomarker correlated with CD8+ T cell and natural killer cell infiltration in skin cutaneous melanoma. *J Clin Med* 2019;8:1993.
52. Michela B. Liquid Biopsy: a family of possible diagnostic tools. *Diagnostics (Basel)* 2021;11:1391.

53. Kumari S, Mukherjee S, Sinha D, Abdisalaam S, Krishnan S, Asaithamby A. Immunomodulatory effects of radiotherapy. *Int J Mol Sci* 2020;21:1–29.
54. Rao Z, Gao J, Zhang B, Yang B, Zhang J. Cisplatin sensitivity and mechanisms of anti-HPV16 E6-ribozyme on cervical carcinoma CaSKI cell line. *Chinese-German J Clin Oncol* 2012;11:237–42.
55. Hill RM, Rocha S, Parsons JL. Overcoming the Impact of Hypoxia in Driving Radiotherapy Resistance in Head and Neck Squamous Cell Carcinoma. *Cancers (Basel)* 2022;14:4130.
56. Liu G, Zhang S, Yang S, Shen C, Shi C, Diao W. CircDiaph3 influences PASM C apoptosis by regulating PI3K/AKT/mTOR pathway through IGF1R. *3 Biotech* 2023;13:342.
57. Deichaite I, Hopper A, Krockenberger L, Sears TJ, Sutton L, Ray X, et al. Germline genetic biomarkers to stratify patients for personalized radiation treatment. *J Transl Med* 2022;20:360. doi: 10.1186/s12967-022-03561-x.
58. Rizzo A, Mollica V, Santoni M, Massari F. Cancer immunotherapy: harnessing the immune system to fight cancer. *J Clin Med* 2022;11:6356. doi: 10.3390/jcm11216356.
59. Nassar SF, Raddassi K, Ubhi B, Doktorski J, Abulaban A. Precision medicine: steps along the road to combat human cancer. *Cells* 2020;9:2056. doi: 10.3390/cells9092056.
60. Puig-Saus C, Sennino B, Peng S, Wang CL, Pan Z, Yuen B, et al. Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy. *Nature* 2023;615:697–704.
61. Berger MF, Mardis ER. The emerging clinical relevance of genomics in cancer medicine. *Nat Rev Clin Oncol* 2018;15:353–65.
62. Talebizadeh P, Babaie M, Brown R, Rahimzadeh H, Ristovski Z, Arai M. The role of non-thermal plasma technique in NOx treatment: A review. *Renewable Sustainable Energy Rev* 2014;40:886–901.
63. Degirmenci U, Wang M, Hu J. Targeting aberrant RAS/RAF/MEK/ERK signaling for cancer therapy. *Cells* 2020;9:198. doi: 10.3390/cells9010198.
64. Lopez JS, Banerji U. Combine and conquer: challenges for targeted therapy combinations in early phase trials. *Nat Rev Clin Oncol* 2017;14:57–66.
65. Mondal M, Guo J, He P, Zhou D. Recent advances of oncolytic virus in cancer therapy. *Hum Vaccin Immunother* 2020;16:2389–402.
66. Zheng M, Huang J, Tong A, Yang H. Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances. *Mol Ther Oncolytics* 2019;15:234–47.
67. Shi T, Song X, Wang Y, Liu F, Wei J. Combining oncolytic viruses with cancer immunotherapy: establishing a new generation of cancer treatment. *Front Immunol* 2020;11:515617. doi: 10.3389/fimmu.2020.00683.
68. Wang T, Xu X, Zhang K. Nanotechnology-enabled chemodynamic therapy and immunotherapy. *Curr Cancer Drug Targets* 2021;21:545–57.
69. Garmaroudi GA, Karimi F, Naeini LG, Kokabian P, Givtaj N. Therapeutic efficacy of oncolytic viruses in fighting cancer: recent advances and perspective. *Oxid Med Cell Longev* 2022; 3142306 doi: 10.1155/2022/3142306.
70. Mukherjee AG, Wanjari UR, Namachivayam A, Murali R, Prabakaran DS, Ganesan R, et al. Role of immune cells and receptors in cancer treatment: an immunotherapeutic approach. *Vaccines (Basel)* 2022;10:1493 doi: 10.3390/vaccines10091493.
71. Pan K, Farrukh H, Chittepu VCSR, Xu H, Pan CX, Zhu Z. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. *J Exp Clin Cancer Res* 2022;41:119. doi: 10.1186/s13046-022-02327-z.
72. Rosenberg SA, Spiess PJ, Kleiner DE. Antitumor effects in mice of the intravenous injection of attenuated *Salmonella typhimurium*. *J Immunother* 2002;25:218–25. doi: 10.1097/01.CJI.0000014623.45316.93.
73. Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. *J Immunol* 2014;192:5451–8. doi: 10.4049/jimmunol.1490019.
74. Qiu Y, Su M, Liu L, Tang Y, Pan Y, Sun J. Clinical application of cytokines in cancer immunotherapy. *Drug Des Devel Ther* 2021;15:2269–87. doi: 10.2147/DDDT.S308578.
75. Winter C, Silvestre-Roig C, Ortega-Gomez A, Lemnitzer P, Poelman H, Schumski A, et al. Chrono-pharmacological Targeting of the CCL2-CCR2 Axis Ameliorates Atherosclerosis. *Cell Metab* 2018;28:175–82.e5. doi: 10.1016/j.cmet.2018.05.002.
76. Aldinucci D, Borghese C, Casagrande N. The CCL5/CCR5 axis in cancer progression. *Cancers (Basel)* 2020;12:1765. doi: 10.3390/cancers12071765.
77. Zeng Z, Lan T, Wei Y, Wei X. CCL5/CCR5 axis in human diseases and related treatments. *Genes Dis* 2022 Jan;9:12–27. doi: 10.1016/j.gendis.2021.08.004.

78. Hamid R, Alaziz M, Mahal AS, Ashton AW, Halama N, Jaeger D, et al. The role and therapeutic targeting of CCR5 in breast cancer. *Cells* 2023;12:2237. doi: 10.3390/cells12182237.
79. Brandum EP, Jørgensen AS, Rosenkilde MM, Hjortø GM. Dendritic cells and CCR7 expression: an important factor for autoimmune diseases, chronic inflammation, and cancer. *Int J Mol Sci* 2021;22:8340. doi: 10.3390/ijms22158340.
80. Yan Y, Chen R, Wang X, Hu K, Huang L, Lu M, et al. CCL19 and CCR7 expression, signaling pathways, and adjuvant functions in viral infection and prevention. *Front Cell Dev Biol* 2019;7:212. doi: 10.3389/fcell.2019.00212.
81. Kadomoto S, Izumi K, Mizokami A. The CCL20–CCR6 axis in cancer progression. *Int J Mol Sci* 2020;21:5186. doi: 10.3390/ijms21155186.
82. Baghban R, Roshangar L, Jahanban–Esfahlan R, Seidi K, Ebrahimi–Kalan A, Jaymand M, et al. Tumor microenvironment complexity and therapeutic implications at a glance. *Cell Commun Signal* 2020;18:59. doi: 10.1186/s12964–020–0530–4.
83. French JA, Koepp M, Naegelin Y, Vigevano F, Auvin S, Rho JM, et al. Clinical studies and anti-inflammatory mechanisms of treatments. *Epilepsia* 2017;58(Suppl 3):69–82. doi: 10.1111/epi.13779.